Lycium, commonly known as goji berry or wolfberry, has been investigated in recent years for its potential benefits in bone health, specifically in the context of osteoporosis. Some preclinical studies have shown that extracts from Lycium barbarum may have a protective effect against bone loss in animal models. These effects are believed to be associated with the antioxidant and anti-inflammatory properties of Lycium polysaccharides, which could help modulate bone remodeling by reducing oxidative stress and inflammation, factors known to contribute to osteoporosis.

For example, studies in ovariectomized rats (a common model for postmenopausal osteoporosis) have demonstrated that Lycium barbarum polysaccharides can improve bone mineral density and alter bone turnover markers. Proposed mechanisms include enhancement of osteoblast (bone-forming cell) activity and inhibition of osteoclast (bone-resorbing cell) activity, as well as modulation of pathways such as RANKL/OPG involved in bone metabolism.

However, the current evidence is limited to animal studies and in vitro experiments. There are no robust clinical trials in humans directly supporting the use of Lycium for osteoporosis prevention or treatment. As such, while there is some scientific rationale and preliminary evidence, the overall quality and quantity of the evidence remain low (rated 2/5), and more rigorous human studies are needed to establish efficacy and safety for this indication.